Nkarta Inc. (NKTX): Price and Financial Metrics
NKTX Price/Volume Stats
| Current price | $7.54 | 52-week high | $16.24 |
| Prev. close | $7.79 | 52-week low | $1.28 |
| Day low | $7.39 | Volume | 235,833 |
| Day high | $7.96 | Avg. volume | 1,912,759 |
| 50-day MA | $10.79 | Dividend yield | N/A |
| 200-day MA | $5.22 | Market Cap | 372.60M |
NKTX Stock Price Chart Interactive Chart >
Nkarta Inc. (NKTX) Company Bio
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Latest NKTX News From Around the Web
Below are the latest news stories about NKARTA INC that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & ExpositionSOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). NKX101 is an allogeneic, off-the-shel |
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to BuyNkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta IncT. Rowe Price Investment Management, Inc. (Trades, Portfolio), a renowned investment firm, has recently adjusted its investment in Nkarta Inc (NASDAQ:NKTX), a biopharmaceutical company. This transaction had a minor impact of -0.01% on the firm's portfolio, with the shares being traded at a price of $2.03. Post-trade, T. Rowe Price Investment Management, Inc. (Trades, Portfolio) holds 430,350 shares of Nkarta Inc, which constitutes a 0.80% stake in the company. |
Nkarta Reports Third Quarter 2023 Financial Results and Corporate HighlightsFDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven safety profileNew pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapyPartnership with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support |
These Biotech Stocks Could Double Your Money, According To AnalystsThe biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate |
NKTX Price Returns
| 1-mo | -41.05% |
| 3-mo | 1.62% |
| 6-mo | 242.73% |
| 1-year | 62.85% |
| 3-year | -75.87% |
| 5-year | N/A |
| YTD | 14.24% |
| 2023 | 10.18% |
| 2022 | -60.98% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...